We are excited to share a recent interview with Vie Ventures Co-Founders Luke Evnin, PhD (SRF Board Chair) and Steven St. Peter, MD hosted on BiotechTV. The interview highlights:
🔹 Why immunology and autoimmunity represent one of the most compelling segments in biotech today
🔹How Vie Ventures aims to accelerate therapies for patients through leadership investing
🔹 How strategic collaboration with leading disease-focused philanthropies creates a differentiated edge
The SRF is a Strategic Collaborator in Vie Ventures, alongside several other leading autoimmune organizations. This collaboration supports key priorities of the SRF: accelerating innovative therapeutics for scleroderma, elevating the disease within the biotech sector, and creating new opportunities to strengthen our research program.
